Intraoperative BradycardiaRAPIDNCT06922097
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
A study testing Giving atropine at heart rates below 60 beats per minute and Giving atropine at heart rates below 30 beats per minute in people with Intraoperative Bradycardia, run by University of Hamburg-Eppendorf at 1 site in Germany.
Trial summary
The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Intraoperative Bradycardia
- What is being tested?
- Giving atropine at heart rates below 60 beats per minute and Giving atropine at heart rates below 30 beats per minute
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 186 participants
- Where
- 1 siteGermany
- Study dates
- 7 Apr 2025to 14 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Patients with the following exclusion criteria: contraindication for atropine administration (e.g., myasthenia gravis, high-grade aortic stenosis, high-grade coronary artery disease, glaucoma, paralytic ileus, prostatic hypertrophy); renal replacement therapy within the previous 3 months; chronic kidney disease with an estimated glomerular filtration rate <20 mL/min/1.73 m2; pregnancy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements: the Randomized RAPID Trial
The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with intraoperative bradycardia.
- Conditions
- Intraoperative Bradycardia
- Being tested
- Giving atropine at heart rates below 60 beats per minute, Giving atropine at heart rates below 30 beats per minute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Giving atropine at heart rates below 60 beats per minuteDrug
In patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
Giving atropine at heart rates below 30 beats per minuteDrug
In patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
| Study group | Role | What they receive |
|---|---|---|
| Giving atropine at heart rates below 60 beats per minute | Experimental | Not described Receives: Drug: Giving atropine at heart rates below 60 beats per minute |
| Giving atropine at heart rates below 30 beats per minute | Active comparator | Not described Receives: Drug: Giving atropine at heart rates below 30 beats per minute |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average norepinephrine infusion rate
Average norepinephrine infusion rate in μg per kg actual body weight per minute (μg kg-1 min-1) needed to keep MAP above 65 mmHg from anesthetic induction until the end of surgery (continuous outcome)
Measured: Perioperative
Secondary outcomes (4)
Time-weighted average MAP <65 mmHg
From anesthetic induction until the end of surgery
Measured: Perioperative
Time-weighted average heart rate <60 bpm
From anesthetic induction until the end of surgery
Measured: Perioperative
Time-weighted average MAP >110 mmHg
From anesthetic induction until the end of surgery
Measured: Perioperative
Time-weighted average heart rate >100 bpm
From anesthetic induction until the end of surgery
Measured: Perioperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2025
- Study start7 Apr 2025
- Primary completion11 Dec 2025
- Study completion14 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraoperative BradycardiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 186 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Hamburg-Eppendorf
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Alina Bergholz, Universitätsklinikum Hamburg-Eppendorf
- Investigators
- Alina Bergholz, MD, Principal investigator, University Medical Centre Hamburg-Eppendorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06922097
- Sponsor's protocol ID
- 2025-101426-BO-ff
- Other IDs
- 2025
- Acronym
- RAPID
- Status last verified
- Aug 2026
- First submitted
- 23 Mar 2025
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements: the Randomized RAPID Trial
- ClinicalTrials.gov ID
- NCT06922097
- Acronym / sponsor ID
- RAPID / 2025-101426-BO-ff
- Conditions
- Intraoperative Bradycardia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 186 participants (actual)
- Lead sponsor
- University of Hamburg-EppendorfUniversity, hospital or other
- Study start
- 7 Apr 2025 (actual)
- Primary completion
- 11 Dec 2025 (actual)
- Study completion
- 14 Dec 2025 (actual)
- First posted
- 10 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with intraoperative bradycardia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Giving atropine at heart rates below 60 beats per minute | Experimental | Drug: Giving atropine at heart rates below 60 beats per minute |
| Giving atropine at heart rates below 30 beats per minute | Active comparator | Drug: Giving atropine at heart rates below 30 beats per minute |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- Patients with the following exclusion criteria: contraindication for atropine administration (e.g., myasthenia gravis, high-grade aortic stenosis, high-grade coronary artery disease, glaucoma, paralytic ileus, prostatic hypertrophy); renal replacement therapy within the previous 3 months; chronic kidney disease with an estimated glomerular filtration rate <20 mL/min/1.73 m2; pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Giving atropine at heart rates below 60 beats per minuteIn patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine. | Drug | Giving atropine at heart rates below 60 beats per minute |
| Giving atropine at heart rates below 30 beats per minuteIn patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine. | Drug | Giving atropine at heart rates below 30 beats per minute |
Primary outcome
Average norepinephrine infusion rate
Time frame: Perioperative
Average norepinephrine infusion rate in μg per kg actual body weight per minute (μg kg-1 min-1) needed to keep MAP above 65 mmHg from anesthetic induction until the end of surgery (continuous outcome)
4 secondary outcomes
Time-weighted average MAP <65 mmHg
Time frame: Perioperative
Time-weighted average heart rate <60 bpm
Time frame: Perioperative
Time-weighted average MAP >110 mmHg
Time frame: Perioperative
Time-weighted average heart rate >100 bpm
Time frame: Perioperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Intraoperative Bradycardia
Not yet recruiting
LLL vs. SDL for LBBP: A Non-inferiority RCT
Bradycardia, Conduction Block, Atrioventricular
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alina Bergholz, MD principal investigator
University Medical Centre Hamburg-Eppendorf
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Giving atropine at heart rates below 60 beats per minute and Giving atropine at heart rates below 30 beats per minute in people with Intraoperative Bradycardia, run by University of Hamburg-Eppendorf at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average norepinephrine infusion rate (time frame: Perioperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.